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Abstract
Background: In Switzerland, oral antibiotics are dispensed in packs rather than by exact pill-count. We investigated
whether available packs support compliance with recommended primary care treatment regimens for common
infections in children and adults.
Methods: Hospital-based guidelines for oral community -based treatment of acute otitis media, sinusitis,
tonsillopharyngitis, community-acquired pneumonia and afebrile urinary tract infection were identified in 2017 in
an iterative process by contacting hospital pharmacists and infectious diseases specialists. Furthermore, newly
available national guidelines published in 2019 were reviewed. Available pack sizes for recommended solid,
dispersible and liquid antibiotic formulations were retrieved from the Swiss pharmaceutical register and compared
with recommended regimens to determine optimal (no leftovers) and adequate (optimal +/− one dose) matches.
Results: A large variety of recommended regimens were identified. For adults, optimal and adequate packs were
available for 25/70 (36%) and 8/70 (11%) regimens, respectively. Pack-regimen matching was better for WHO Watch
(optimal: 15/24, 63%) than Access antibiotics (optimal: 7/39, 18%). For the four paediatric weight-examples and 42
regimens involving child-appropriate formulations, optimal and adequate packs were available for only 14/168 (8%)
and 27/168 (16%), respectively. Matching was better for older children with higher body and for longer treatment
courses > 7 days.
Conclusions: Fixed antibiotic packs often do not match recommended treatment regimens, especially for children,
potentially resulting in longer than necessary treatments and leftover doses in the community. As part of national
stewardship, a move to an exact pill-count system, including for child-appropriate solid formulations, should be
considered.
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Background
Antibiotic resistance is increasingly becoming a global
challenge to human health [1]. The use of leftover pre-
scribed antibiotics has been shown to be a source of
self-medication and overuse of antibiotics, potentially
driving resistance emergence and spread [2–4]. In
Switzerland and many other countries, antibiotics are dis-
pensed in fixed packs. Such dispensation practices appear
to be a strong factor in determining possession of leftovers
in the ambulatory setting [5]. A potential mismatch be-
tween clinical practice guidelines and packs could consid-
erably influence the amount of leftover antibiotics, and
therefore contribute to antibiotic misuse and overuse [6–
9]. The trend towards shorter durations of antibiotic treat-
ments could aggravate this problem if pack size remains
unrevised especially for older antibiotics [10].
In 2017, the World Health Organisation (WHO) de-
fined antibiotic groups (Access, Watch, Reserve) that are
to be used globally for national stewardship based on
their likely ecologic impact on antimicrobial resistance
[11]. In 2019, a recommendation for at least 60% of all
antibiotics used at a national level to be from the so-
called Access group followed [12]. It is unclear whether
there could be a differential pack-regimen mismatch for
Access compared with other antibiotics, given that many
Access antibiotics are older agents that came to market
when longer treatment durations were favoured [10, 13].
This could potentially drive preferential prescribing of
Watch antibiotics to support currently recommended
shorter treatment durations.
We investigated whether antibiotic packs available in
Switzerland correspond to, and therefore support com-
pliance with, treatment regimens specified in clinical
practice guidelines for common infections in children
and adults treated in primary care. As a secondary ob-
jective we evaluated the types of antibiotics most com-
monly involved in mismatches with respect to the new
WHO Access, Watch, Reserve (AWaRe) grouping of an-
tibiotics for stewardship.
Methods
In Switzerland, a system of compulsory health insurance
covers most healthcare costs. Non-profit insurers, ap-
proved by the government, offer a basic mandatory in-
surance and voluntary top-up plans covering special
conditions or additional services [14]. Prescribed medi-
cines from the “list of pharmaceutical specialties”, such
as oral antibiotics, are generally reimbursed by basic
insurance [15, 16].
Guidelines
Five infections frequently treated with oral antibiotics in
the primary care setting in children and adults (otitis
media, sinusitis, tonsillopharyngitis, community-acquired
pneumonia (CAP), afebrile urinary tract infections (UTI))
were selected for this study. For these, we collected
hospital-based treatment guidelines in an iterative process
during July 2017–November 2017 by (i) posting a request
on the online forum of the Swiss association of Public
Health Administration and Hospital Pharmacists, (ii) dir-
ectly contacting infectious diseases specialists at selected
centres and (iii) searching online for open access hospital
guidelines.
We specifically focused on obtaining information from
designated training hospitals for infectious diseases. Add-
itional guidelines from non-training hospitals were also
considered and included if their recommendations devi-
ated. When national recommendations became available
in 2019 for otitis media, sinusitis, tonsillopharyngitis and
adult afebrile UTI, these were included [17]. We assume
that a considerable proportion of prescribers is likely to be
using local older recommendations during a transitional
period as well as for CAP pending national guidance.
Antibiotic formulations and packs
All formulations, packs and brands for the antibiotics
recommended in the identified guidelines were retrieved
from Compendium®, the pharmaceutical register of all
medications available in Switzerland, excluding those
imported from foreign countries [18].
We divided oral formulations into 3 groups: solid (tab-
lets, capsules), dispersible (tablets, granules) and liquid
(suspension, powder for oral suspension). Only liquids
were considered child-appropriate, because children
younger than school age are unlikely to be able to swal-
low monolithic solid formulations [19]. Furthermore,
solids and dispersible tablets are licensed only in patients
weighing more than 40 kg in Switzerland, so their use
would be considered off-label in young children. Slow
release formulations were not included because of their
absence of recommendation in the guidelines, with the
exception of nitrofurantoin.
Identification of recommended regimens
Data on the following aspects of each regimen and infec-
tion were entered onto an online REDCap™ database:
recommended drug, single dose, dosing frequency and
duration of treatment, recommended first or second-line
or in special instances (drug allergy) [20]. Recommenda-
tions for “simple urinary tract infection” were inter-
preted as only applicable to women.
We analysed all possible oral antibiotic regimens for
all recommended active substances by infection: For
adult patients, we calculated the required number of
solid or dispersible dosing units per regimen. In cases of
treatment duration ranges, the required number of dos-
ing units for the minimal and maximal duration was de-
termined and only the extremes were evaluated as no
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assumptions about the commonly selected durations
were possible.
As paediatric prescribing in Switzerland is weight-
based, we used four weight-examples to evaluate pack
and regimen matches at body weights of 10 kg (corre-
sponding to roughly 15 months of age), 15 kg (roughly
3.5 years), 20 kg (roughly 6 years) and 25 kg (roughly
8 years) [21].
For formulations with amoxicillin and enzyme inhibi-
tor, all calculations were based on the amoxicillin con-
tent whereas for cotrimoxazole, we considered the total
amount of both substances together. For paediatric
amoxicillin/clavulanate use, we limited ourselves to 7:1
ratio formulations.
Determination of matching of available packs and
regimens
Based on the above data, regimens were matched with
available packs and were categorized into three groups:
optimal match (no leftover doses for recommended regi-
men), adequate match (optimal +/− one single dose
compared to recommended regimen), no match (+/−
more than two doses compared to recommended regi-
men necessary to match pack). For children, we followed
the same approach by calculating the total amount re-
quired for a treatment course for all identified regimens
by weight-example. Pack-regimen matching was done as
for adults but limited to child-appropriate liquid formu-
lations. We assumed that dispensation of several packs,
when required, would involve only one type of pack and
formulation concentration. Combinations of different
packs per drug were not considered.
Matching patterns according to access and Watch WHO
antibiotic groups
We reviewed pack-regimen matching by Access and
Watch groups as defined in the 2017 revision of the
WHO Model list of Essential Medicines, considering
only core Access antibiotics as part of the Access group
[11]. Access-Watch antibiotics were included in the
Watch group. Oral fosfomycin and cefuroxime were not
listed and thus excluded from this analysis.
Results
Guidelines
For adults, 16 different hospitals provided guidelines, of
which 14 were included in our study since they provided
specific recommendations for the infections of interest
(Additional file 1). Together with national guidelines,
there were 11 different treatment guidelines for each in-
fection with the exception of CAP with 10 guidelines
and UTI in men with only six guidelines. For children,
six hospitals (three university level and three regional
hospitals) provided guidelines, all were included in our
study. We were not able to obtain paediatric guide-
lines from the French part of Switzerland. All in-
cluded guidelines contained recommendations for
otitis media and tonsillopharyngitis. As updated na-
tional paediatric guidelines for UTI and CAP are not
yet available, there were only six guidelines for these
two infections, and treatment recommendations for
sinusitis were only found in five guidelines.
Treatment regimens
For adults, 70 regimens involving 15 antibiotics differ-
ing in single dose, dosing frequency and duration
were identified; some were only recommended as
second-line treatment, for example in the context of
penicillin allergy (Additional file 2). For children, 52
oral treatment regimens for 11 substances were iden-
tified (Additional file 2).
In general, we observed a big difference in the diversity
of the recommendations between infections. In both
adults and children, the greatest number of treatment
regimens was identified for CAP (31 for adults, involving
7 different antibiotics with treatment durations of five to
10 days; 22 for children, involving 6 antibiotics with du-
rations of three to 10 days). The number of regimens for
sinusitis, acute otitis media and streptococcal tonsillo-
pharyngitis was generally higher for adults than for chil-
dren (32 versus 8, 28 versus 11 and 21 versus 13,
respectively). As similar numbers of individual agents
were involved, these differences generally were related to
higher variability in combinations of single dose, dosing
frequency and duration. In contrast, we found only nine
different regimens for UTI in women and seven regi-
mens for UTI in men. For afebrile urinary tract infection
in children there was a bigger variety of 13 different reg-
imens involving five antibiotics. Treatment durations for
afebrile UTI were relatively short, ranging from one to 7
days depending on age, sex and antibiotic used.
Available oral antibiotic formulations
In total, fifteen antibiotics from the above regimens were
of interest with solid and at least one liquid formulation
being available for nine of these (no liquid formulations
for norfloxacin, levofloxacin, moxifloxacin, doxycycline,
fosfomycin and nitrofurantoin, Additional file 3). Corres-
pondingly, paediatric guidelines only made recommen-
dations for nitrofurantoin and doxycycline in children
older than 8 years not covered by our weight-examples.
Matching of recommended regimens and packs
For adults, optimal packs were available for only 36%
(25/70) of recommended regimens and for an additional
11% (8/70) packs were adequate (Table 1 and Additional
file 2). For the remaining 53% (37/70), no matching
packs could be found.
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menSubstance Single dose N doses/day Duration (in days)
WHO group: ACCESS
Amoxicillin 375 mg 3 5 15 (+ 1)
500 mg 3 7 21 (−1)
750 mg 3 7 21 (−1) 21 (− 1) 21 (− 1)
1000mg 2 5 10 10a
1000mg 2 7 14 14a
1000mg 3 5 15 (−1) 15 (−1)a 15 (−1)a
1000mg 3 7 21 (−1) 21 (− 1)
Amoxicillin/clavulanate 625 mg 3 3 9 (+ 1)a
625mg 3 7 21 (−1) 21 (−1) 21 (− 1)
1000mg 2 10 20 20 20
1000mg 4 5 20a
Doxycycline 100mg 2 5 10 10 10a
Cotrimoxazole 960mg 2 5 10a 10 10
960mg 2 10 20
WHO group: WATCH
Azithromycin 500mg 1 3 3 3 3
500mg 1 5 5(+ 1) 5(+ 1)
Ciprofloxacin 500mg 2 5 10
Clarithromycin 250mg 2 7 14 14
250mg 2 10 20
500mg 2 7 14 14
500mg 2 10 20 20 20
Levofloxacin 500mg 1 5 5 5
500mg 1 7 7 7
500mg 1 10 10
500mg 2 5 10
500mg 2 7 14
Moxifloxacin 400mg 1 5 5
400mg 1 7 7 7
400mg 1 10 10 10
Norfloxacin 400mg 2 3 6a
WHO group: UNCLASSIFIED
Cefuroxime 250mg 2 7 14 14
500mg 2 7 14 14 14a 14a
Fosfomycin 3000mg 1 1 1a
apart of the SSI-Guidelines (ssi.guidelines.ch)
+1 = optimized by adding a single dose; -1 = optimized by subtracting a single dose
CAP Community-acquired pneumonia, UTI Urinary tract infection
The regimens are shown together with the number of dosing units required for that regimen. Antibiotics are listed alphabetically by WHO Access or Watch
groups with unclassified antibiotics listed separately. Bold font indicates availability of an optimal pack for the listed antibiotic and regimen. Normal font indicates
availability of an adequate pack for the listed antibiotic and regimen, meaning that matching could be achieved by adding or dropping a single dosing unit.
Listed regimens represent 47.1% (33/70 regimens) for adults. All remaining regimens did not have matching optimal or adequate packs
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Antibiotics with optimal matching for all recommenda-
tions were oral fosfomycin, moxifloxacin and norfloxacin.
Antibiotics without matching for any recommendations
were clindamycin, nitrofurantoin and phenoxymethylpeni-
cillin. For nine of 15 antibiotics < 50% optimal or adequate
pack sizes existed for the recommended regimens. Amoxi-
cillin packs matched only a small number of regimens (2/
15 regimens, 13%) as did those for amoxicillin/clavulanate
(2/12 regimens, 17%), despite these two antibiotics having
the highest diversity of regimens.
For children, we matched 42 treatment regimens of
nine antibiotics with child-appropriate liquid formula-
tions available for four weight-examples. Optimal
packs existed only for 8% (14/168) of regimens, with
adequate packs available for another 16% (27/168)
(Tables 2, 3, 4, 5 and Additional file 2).
For the remaining 76% (127/168), no matching packs
could be found. We observed best matching for amoxi-
cillin regimens (4/28, 14%). Despite three different avail-
able pack sizes for amoxicillin/clavulanate and 13
different regimens, only 12% (6/52) had optimal packs.
We could not find any suitable packs for the considered
weight-examples for ciprofloxacin, clarithromycin, phe-
noxymethylpenicillin and cotrimoxazole. For lighter and
therefore younger children (10 kg, 15 kg) matching was
poorer than for heavier older children (20 kg, 25 kg).
Comparing optimal versus adequate packs, there were
more optimal packs available for regimens with longer
duration, especially in younger children.
Matching according to the WHO AWaRe groups
For adults, optimal and adequate packs existed for only
18% (7/39) and 18% (7/39) regimens involving Access
antibiotics (Table 1 and Additional file 4). For the
remaining 64% (25/39) no matching packs could be
found. In contrast optimal packs were available for 63%
(15/24) of regimens involving Watch antibiotics.
For children, a very low rate of optimal available
packs was found for both groups (9% in the Access
group, 4% in the Watch group, Tables 2, 3, 4, 5 and
Additional file 4). We also observed a larger range of
different regimens (N = 12–52) for Access antibiotics
than for Watch antibiotics (N = 4–12).
Discussion
Our analysis of pack-regimen matching showed an im-
portant mismatch between recommended oral regimens
for infections commonly treated in the community setting
and available pack sizes for antibiotics in Switzerland.
For adults, a suitable pack could be found for only
36% of the considered regimens, and for child-
appropriate formulations this rate was even lower at 8%
based on four weight-examples. In adults, all antibiotics
with high rates of suitable packs were from the WHO
Watch group [10]. This is an alarming fact from the per-
spective of antibiotic stewardship: Dispensing of Watch
antibiotics in Switzerland seems paradoxically easier
than dispensing of Access antibiotics, with better pack-
regimen matching.




UTISubstance Single dose N doses/day Duration (in days)
WHO group: ACCESS
Amoxicillin 25mg/kg 2 10 1 1a 1a
Amoxicillin/clavulanate 25mg/kg 2 5 0.89 (+ 1)
26.7mg/kg 3 7 1
40mg/kg 2 3 0.86 (+ 1)
40mg/kg 2 7 1
40mg/kg 2 14 1a
Clindamycin 7 mg/kg 3 6 1.05 (−1)a
WHO group: WATCH
Azithromycin 10mg/kg 1 5 0.83 (+ 1)
WHO group: UNCLASSIFIED
Cefuroxime 15mg/kg 2 5 0.86 (+ 1) 0.86 (+ 1)a 0.86 (+ 1) 0.86 (+ 1)
15 mg/kg 2 6 1.03 (−1)a
apart of the SSI-Guidelines (ssi.guidelines.ch)
+1 = optimized by adding a single dose; -1 = optimized by subtracting a single dose
CAP Community-acquired pneumonia, UTI Urinary tract infection
The regimens are shown together with the number of dosing units required for that regimen. Antibiotics are listed alphabetically by WHO Access or Watch
groups with unclassified antibiotics listed separately. Bold font indicates availability of an optimal pack for the listed antibiotic and regimen. Normal font indicates
availability of an adequate pack for the listed antibiotic and regimen, meaning that matching could be achieved by adding or dropping a single dosing unit to
the regimen or leftovers of < one single dosing unit. Listed regimens represent 24.4% (10/42 regimens) in this weight-example. All remaining regimens did not
have matching optimal or adequate packs
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UTISubstance Single dose N doses/day Duration (in days)
WHO group: ACCESS
Amoxicillin 25 mg/kg 2 7 1.05 (−1)
Amoxicillin/clavulanate 25 mg/kg 2 3 0.80 (+ 1)
25 mg/kg 2 7 0.94
WHO group: WATCH
Azithromycin 10 mg/kg 1 3 0.75 (+ 1) 0.75 (+ 1)
10 mg/kg 1 5 1.25 (−1)
WHO group: UNCLASSIFIED
Cefuroxime 15 mg/kg 2 7 1.8 (+ 1)
+ 1 = optimized by adding a single dose; − 1 = optimized by subtracting a single dose
CAP Community-acquired pneumonia, UTI Urinary tract infection
The regimens are shown together with the number of dosing units required for that regimen. Antibiotics are listed alphabetically by WHO Access or Watch
groups with unclassified antibiotics listed separately. Bold font indicates availability of an optimal pack for the listed antibiotic and regimen. Normal font indicates
availability of an adequate pack for the listed antibiotic and regimen, meaning that matching could be achieved by adding or dropping a single dosing unit to
the regimen or leftovers of < one single dosing unit. Listed regimens represent 14.6% (6/42 regimens) in this weight-example. All remaining regimens did not
have matching optimal or adequate packs




UTISubstance Single dose N doses/day Duration (in days)
WHO group: ACCESS
Amoxicillin 25mg/kg 2 5 1a
25mg/kg 2 10 2 2a 2a
Amoxicillin/clavulanate 25 mg/kg 2 5 0.89 (+ 1)
26.7 mg/kg 3 3 0.86 (+ 1)
26.7mg/kg 3 7 1
40 mg/kg 2 3 0.86 (+ 1)
40mg/kg 2 7 1
40mg/kg 2 14 2a
Clindamycin 7 mg/kg 3 6 2.1 (−1)a
10mg/kg 3 10 5
WHO group: WATCH
Azithromycin 10mg/kg 1 3 1 1
10 mg/kg 1 5 0.83 (+ 1)
WHO group: UNCLASSIFIED
Cefuroxime 15 mg/kg 2 5 1.7 (+ 1) 1.7 (+ 1)a 1.7 (+ 1) 1.7 (+ 1)
15 mg/kg 2 6 2.06 (−1)a
15 mg/kg 2 14 4.8 (+ 1)a
apart of the SSI-Guidelines (ssi.guidelines.ch)
+ 1 = optimized by adding a single dose; − 1 = optimized by subtracting a single dose
CAP Community-acquired pneumonia, UTI Urinary tract infection
The regimens are shown together with the number of dosing units required for that regimen. Antibiotics are listed alphabetically by WHO Access or Watch
groups with unclassified antibiotics listed separately. Bold font indicates availability of an optimal pack for the listed antibiotic and regimen. Normal font indicates
availability of an adequate pack for the listed antibiotic and regimen, meaning that matching could be achieved by adding or dropping a single dosing unit to
the regimen or leftovers of < one single dosing unit. Listed regimens represent 36.6% (15/42 regimens) in this weight-example. All remaining regimens did not
have matching optimal or adequate packs
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For children very low rates of suitable packs were avail-
able. Moving from exact weight-based to weight-banded
dosing with appropriate packs, and greater advocacy for
the development and licensing of dispersible or mini-
tablets could mitigate some of the specific challenges [19,
22]. Indeed, despite the current situation, use of child-
appropriate formulations of Access antibiotics in
Switzerland is high (> 85%) [23]. Packs often seem adapted
to cater to older (and heavier) children and longer treat-
ment durations with poorer compliance [24]. Considering
they experience the highest rates of community-based
antibiotic prescribing, the fewest suitable packs for
evidence-based shorter treatment durations were available
for children less than 5 years of age [23]. In contrast, some
regimens could only be achieved by dispensing multiple
packs, increasing the risk that a second package is not ad-
ministered and kept at home for future use as well as of
environmental contamination on disposal.
Similar mismatches between recommended regimens
and available pack sizes have been documented in
Croatia, India and Australia, with this phenomenon
thought to account for a substantial proportion of “re-
dundant antibiotic doses in the community” [6, 8, 9].
Antibiotics dispensed in fixed packs seem to be a risk
factor for leftovers in adults. Kardas and colleagues de-
scribe a higher tendency for patients in “pack-countries”
to save leftovers or give them to others than in “pill-
countries” where the exact amount of pills required per
course is dispensed [5]. Leftover antibiotics are also
often disposed in the household waste or flushed down
the toilet which can contribute to the development of
antibiotic resistance [25].
The strength of our study is that we most likely were
able to identify the majority of frequently used regimens
for five infections commonly managed in primary care
and combined these with comprehensive information on
available antibiotic packs in Switzerland. Furthermore,
we covered the whole population of adults and children
in our analysis. We anticipate that our observations will
be applicable to many other pack-dispensing countries.
Our study also has limitations. We focused on hospital
guidelines and very recent national recommendations. In
general, all community prescribers in Switzerland will
undergo hospital-based training, and current prescribers
will most likely have been exposed to hospital antibiotic
policies during their training [26, 27]. We also selected
certain infections based on their considerable contribu-
tion to antibiotic prescribing in the community. Antibi-
otics and treatment regimens may differ for other
common infections, such as skin and soft tissue infec-
tions, with potentially better matching with available
packs. When treatment ranges were given, we only con-
sidered the minimal and maximal duration, but dura-
tions in between may also be chosen. In certain cases,
such an intermediate duration could provide an optimal
or adequate match with an available pack. Of note, some
intermediate durations may actually have been repre-
sented in another included recommendation. We




UTISubstance Single dose N doses/day Duration (in days)
WHO group: ACCESS
Amoxicillin 40mg/kg 2 5 2
40 mg/kg 2 7 2.8 (+ 1)
Amoxicillin/clavulanate 26.7 mg/kg 3 5 0.89 (+ 1)
40 mg/kg 2 5 0.89 (+ 1) 0.89 (+ 1)a 0.89 (+ 1)
Cotrimoxazole 18 mg/kg 2 5 0.94 0.94
18 mg/kg 2 10 1.88 (+ 1)
WHO group: WATCH
Azithromycin 10 mg/kg 1 3 1.25 (−1) 1.25 (− 1)
10 mg/kg 1 5 1.04 (−1)
WHO group: UNCLASSIFIED
Cefuroxime 15mg/kg 2 7 3
15mg/kg 2 14 6a
apart of the SSI-Guidelines (ssi.guidelines.ch)
+ 1 = optimized by adding a single dose; − 1 = optimized by subtracting a single dose
CAP Community-acquired pneumonia, UTI Urinary tract infection
The regimens are shown together with the number of dosing units required for that regimen. Antibiotics are listed alphabetically by WHO Access or Watch
groups with unclassified antibiotics listed separately. Bold font indicates availability of an optimal pack for the listed antibiotic and regimen. Normal font indicates
availability of an adequate pack for the listed antibiotic and regimen, meaning that matching could be achieved by adding or dropping a single dosing unit to
the regimen or leftovers of < one single dosing unit. Listed regimens represent 24.4% (10/42 regimens) in this weight-example. All remaining regimens did not
have matching optimal or adequate packs
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incorporated the regimens with one missing single dose
in the adequate match group because we considered one
missing dose of a regimen to be clinically acceptable.
However, this could be result in the dispensation of an
additional full pack and increase the risk of leftover anti-
biotics. In children, we analysed only four weight exam-
ples and sometimes slightly higher or lower weight may
achieve good matching. This makes an exact evaluation
complex, as leftover dose units will differ by weight. It
also demonstrates the potential negative impact of exact
weight-based dosing using suspensions on matching of
treatment recommendations and available pack sizes. Fi-
nally, even with perfect matching of available packs and
treatment regimens adherence may be suboptimal and
doses may be left over.
Conclusions
This study highlights that fixed packs of antibiotics in
Switzerland often do not fit with the recommended
treatment regimens. Influencing pack sizes to ensure
that optimal packs for shortest evidence-based regimens
are available is challenging, with complex economic and
regulatory implications. Furthermore, the same antibi-
otics are likely to be used differently for the treatment of
different infections. As part of national stewardship ef-
forts, consideration should therefore be given to moving
to an exact pill-count system for adults and advocating
for weight-banded dosing approaches or child-
appropriate solid formulations for children. Exact pill-
count dispensation in particular would support wider
use of short Access antibiotic treatment courses and
could enable personalised treatment regimens based on
stratification factors in the future.
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